180 related articles for article (PubMed ID: 28750665)
21. Pemetrexed-induced scleroderma-like conditions in the lower legs of a patient with non-small cell lung carcinoma.
Ishikawa K; Sakai T; Saito-Shono T; Miyawaki M; Osoegawa A; Sugio K; Ono A; Mori H; Nishida H; Yokoyama S; Okamoto O; Fujiwara S; Hatano Y
J Dermatol; 2016 Sep; 43(9):1071-4. PubMed ID: 26992088
[TBL] [Abstract][Full Text] [Related]
22. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy-induced cardiomyopathy caused by Pemetrexed.
Oyakawa T; Iida K; Kusuhara M; Kenmotsu H; Sugino T
Invest New Drugs; 2018 Feb; 36(1):147-150. PubMed ID: 28660548
[TBL] [Abstract][Full Text] [Related]
24. Interstitial pneumonitis after treatment with pemetrexed: a rare event?
Hochstrasser A; Benz G; Joerger M; Templeton A; Brutsche M; Früh M
Chemotherapy; 2012; 58(1):84-8. PubMed ID: 22377772
[TBL] [Abstract][Full Text] [Related]
25. Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies.
Langer CJ; Paz-Ares LG; Wozniak AJ; Gridelli C; de Marinis F; Pujol JL; San Antonio B; Chen J; Liu J; Oton AB; Visseren-Grul C; Scagliotti GV
Clin Lung Cancer; 2017 Sep; 18(5):489-496. PubMed ID: 28479368
[TBL] [Abstract][Full Text] [Related]
26. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
27. Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions.
Elsoueidi R; Lander MJ; Richa EM; Adane ED
J Oncol Pharm Pract; 2016 Apr; 22(2):271-4. PubMed ID: 25908647
[TBL] [Abstract][Full Text] [Related]
28. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review.
Zattera T; Londrino F; Trezzi M; Palumbo R; Granata A; Tatangelo P; Corbani V; Falqui V; Chiappini N; Mathiasen L; Cavallini M; Rolla D
J Nephropathol; 2017 Mar; 6(2):43-48. PubMed ID: 28491851
[TBL] [Abstract][Full Text] [Related]
30. Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
Sassier M; Dugué AE; Clarisse B; Lesueur P; Avrillon V; Bizieux-Thaminy A; Auliac JB; Kaluzinski L; Tillon J; Robinet G; Le Caer H; Monnet I; Madroszyk A; Boza G; Falchero L; Fournel P; Egenod T; Toffart AC; Leiber N; Do P; Gervais R
Lung Cancer; 2015 Aug; 89(2):161-6. PubMed ID: 26037036
[TBL] [Abstract][Full Text] [Related]
31. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
Ciuleanu T; Brodowicz T; Zielinski C; Kim JH; Krzakowski M; Laack E; Wu YL; Bover I; Begbie S; Tzekova V; Cucevic B; Pereira JR; Yang SH; Madhavan J; Sugarman KP; Peterson P; John WJ; Krejcy K; Belani CP
Lancet; 2009 Oct; 374(9699):1432-40. PubMed ID: 19767093
[TBL] [Abstract][Full Text] [Related]
32. Incidence of cutaneous reactions with pemetrexed: Comparison of patients who received three days of oral dexamethasone twice daily to patients who did not.
Clark SK; Anselmo LM
J Oncol Pharm Pract; 2019 Oct; 25(7):1645-1650. PubMed ID: 30319062
[TBL] [Abstract][Full Text] [Related]
33. Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
Hata A; Katakami N; Hattori Y; Tanaka K; Fujita S; Kotani Y; Nishimura T; Imamura F; Yokota S; Satouchi M; Monden K; Otsuka K; Nishiyama A; Tsubouchi K; Kaneda T; Yoshioka H; Morita S; Negoro S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):689-695. PubMed ID: 28280972
[TBL] [Abstract][Full Text] [Related]
34. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Gridelli C; de Marinis F; Pujol JL; Reck M; Ramlau R; Parente B; Pieters T; Middleton G; Corral J; Winfree K; Melemed S; Zimmermann A; John W; Beyrer J; Chouaki N; Visseren-Grul C; Paz-Ares LG
J Thorac Oncol; 2012 Nov; 7(11):1713-21. PubMed ID: 23059776
[TBL] [Abstract][Full Text] [Related]
35. [Pemetrexed-induced cutaneous sclerosis of the lower limbs].
Sarrazin M; Levavasseur M; Fadin A; Dezoteux F; Staumont-Sallé D
Ann Dermatol Venereol; 2020 Dec; 147(12):842-847. PubMed ID: 32763003
[TBL] [Abstract][Full Text] [Related]
36. Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer.
Jung YD; Lee SB; Jung YW; Song JS; Woo IS
Korean J Intern Med; 2017 Sep; 32(5):923-925. PubMed ID: 28298078
[No Abstract] [Full Text] [Related]
37. [Pemetrexed-induced scleroderma-like changes in the lower legs].
Corbaux C; Marie J; Meraud JP; Lacroix S; Delhoume JY; Jouary T; Madoui S
Ann Dermatol Venereol; 2015 Feb; 142(2):115-20. PubMed ID: 25554663
[TBL] [Abstract][Full Text] [Related]
38. Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.
Miyahara T; Sueoka-Aragane N; Iwanaga K; Ureshino N; Komiya K; Nakamura T; Nakashima C; Abe T; Matsunaga H; Kimura S
Med Oncol; 2017 Nov; 34(12):195. PubMed ID: 29124473
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
[TBL] [Abstract][Full Text] [Related]
40. Kidney tubular toxicity of maintenance pemetrexed therapy.
Glezerman IG; Pietanza MC; Miller V; Seshan SV
Am J Kidney Dis; 2011 Nov; 58(5):817-20. PubMed ID: 21849225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]